Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies Life Science Investing News
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis Pharmaceutical Investing
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial SmartNews
Results From RMWC Funded Phase II Prostate Cancer Trial using INV043 – Strong Safety Profile and 40% Positive Response Rate Pharmaceutical Investing
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 Geography
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14 Pharmaceutical Investing
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation Pharmaceutical Investing
